A5029207281- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cancer Research and Treatments
- vaccines and immunoinformatics approaches
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- T-cell and B-cell Immunology
- Antimicrobial Peptides and Activities
- Immune Response and Inflammation
- Occupational and environmental lung diseases
- Virus-based gene therapy research
- Nanoplatforms for cancer theranostics
- RNA Interference and Gene Delivery
- Pleural and Pulmonary Diseases
Ultimovacs (Norway)
2021-2024
Oslo University Hospital
2002-2023
University of Oslo
2021-2023
Faculty (United Kingdom)
2022
Norwegian Cancer Society
2021-2022
Cancer vaccines represent a novel treatment modality with complementary mode of action addressing crucial bottleneck for checkpoint inhibitor (CPI) efficacy. CPIs are expected to release brakes in T-cell responses elicited by vaccination, leading more robust immune responses. Increased antitumor may confer increased activity patients less immunogenic tumors, subgroup achieve reduced benefit from alone. In this trial, telomerase-based vaccine was combined pembrolizumab assess the safety and...
Background Ipilimumab improves survival for patients with metastatic malignant melanoma. Combining a therapeutic cancer vaccine ipilimumab may increase efficacy by providing enhanced anti-tumor immune responses. UV1 consists of three synthetic long peptides from human telomerase reverse transcriptase (hTERT). These comprise epitopes recognized T cells experiencing long-term following treatment first-generation hTERT vaccine, and generate long-lasting responses in when used as monotherapy....
Background Therapeutic cancer vaccines represent a promising approach to improve clinical outcomes with immune checkpoint inhibition. UV1 is second generation telomerase-targeting therapeutic vaccine being investigated across multiple indications. Although telomerase near-universal tumor target, different treatment combinations applied indications may affect the induced response. Three phase I/IIa trials covering malignant melanoma, non-small cell lung cancer, and prostate have been...
Abstract Background This clinical trial evaluated a novel telomerase-targeting therapeutic cancer vaccine, UV1, in combination with ipilimumab, patients metastatic melanoma. Translational research was conducted on patient-derived blood and tissue samples the goal of elucidating effects treatment T cell receptor repertoire tumor microenvironment. Methods The an open-label, single-center phase I/IIa study. Eligible had unresectable Patients received up to 9 UV1 vaccinations four ipilimumab...
Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour. For patients with inoperable disease, few treatment options are available after first line chemotherapy. The combination of ipilimumab nivolumab has recently shown increased survival compared to standard chemotherapy, but most do not respond improvements called for. Telomerase expressed in cells, only sparsely normal tissues therefore an attractive target for therapeutic vaccination. Vaccination against telomerase...
Accurate and full-length typing of the HLA region is important in many clinical research settings. With advent next generation sequencing (NGS), several algorithms have been developed, including that are applicable to whole exome (WES). However, most these solutions operate by providing closest-matched allele among known alleles IPD-IMGT/HLA Database. These database-matching approaches demonstrated very high performance when well characterized alleles. as they rely on completeness database,...
Therapeutic cancer vaccines are novel immuno-therapeutics, aiming to improve clinical outcomes with other immunotherapies. However, obstacles their successful development remain, which model-informed drug approaches may address. UV1 is a telomerase based therapeutic vaccine candidate being investigated in phase I trials for multiple indications. We developed mechanism-based model structure, using nonlinear mixed-effects modeling techniques, on longitudinal tumor sizes (sum of the longest...
Abstract Human telomerase reverse transcriptase (hTERT) vaccine has found to be effective for most of the participated de novo metastatic prostate cancer patients in clinical studies. Nevertheless, molecular mechanisms behind immune response induced by hTERT are not fully elucidated. Among cohort 21 treated with androgen deprivation therapy, radiotherapy and vaccine, we used RNA-sequencing TCR-sequencing (20 14 pre-treatment 20 post-treatment samples, respectively) inspect changes...
<p>Figure S2</p>
<p>Table S2</p>
<p>Figure S1</p>
<div>Abstract<p><b>Purpose:</b> Cancer vaccines represent a novel treatment modality with complementary mode of action addressing crucial bottleneck for checkpoint inhibitor (CPI) efficacy. CPIs are expected to release brakes in T-cell responses elicited by vaccination, leading more robust immune responses. Increased anti-tumor may confer increased activity patients less immunogenic tumors, subgroup achieve reduced benefit from alone. In this trial, telomerase-based...
<p>Figure S2</p>
<p>Table S1</p>
<p>Figure S1</p>
<p>Table S1</p>
<p>Figure S3</p>
<p>Table S2</p>
<p>Figure S3</p>
<div>AbstractPurpose:<p>Cancer vaccines represent a novel treatment modality with complementary mode of action addressing crucial bottleneck for checkpoint inhibitor (CPI) efficacy. CPIs are expected to release brakes in T-cell responses elicited by vaccination, leading more robust immune responses. Increased antitumor may confer increased activity patients less immunogenic tumors, subgroup achieve reduced benefit from alone. In this trial, telomerase-based vaccine was combined...
62 Background: Combining checkpoint blockade with a cancer vaccine may induce broader immune responses, leading to better clinical outcomes. UV1 targets the enzyme telomerase (hTERT) which is expressed in almost all types and essential for immortality of cells hallmark cancer. consists three synthetic long peptides vaccination induces Th1 responses most patients irrespective HLA type. This trial explores synergistic effect CTLA-4 hTERT vaccination, allowing unchecked expansion hTERT-specific...
<p>Table S1</p>